Cellectar Biosciences Inc  

(Public, OTCMKTS:CLRB)   Watch this stock  
Find more results for Simon Pedder�
-0.10 (-1.49%)
Delayed:   11:04AM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 6.60 - 6.60
52 week 5.00 - 9.20
Open 6.60
Vol / Avg. 180.00/1,592.00
Mkt cap 18.94M
P/E     -
Div/yield     -
EPS -3.58
Shares 2.87M
Beta -0.01
Inst. own 12%
May 14, 2014
Q1 2014 Cellectar Biosciences, Inc. Earnings Conference Call
May 14, 2014
Q1 2014 Cellectar Biosciences, Inc. Earnings Release

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -158.94% -117.88%
Return on average equity -2428.61% -181.86%
Employees 24 -
CDP Score - -


3301 Agriculture Drive
United States - Map
+1-617-2441616 (Phone)
+1-608-4418121 (Fax)

Website links


Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc. is engaged in developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a phospholipid ether (PLE) platform technology as a targeted delivery and retention vehicle, its compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. The Company�s portfolio consists of PET imaging agents, optical imaging agents and therapeutic agents. The Company's I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. Its I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Its CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

Officers and directors

Stephen Anthony Hill M.D. Chairman of the Board
Age: 55
Simon Pedder Ph.D. President, Chief Executive Officer, Director
Age: 52
Chad J. Kolean Chief Financial Officer, Vice President - Finance, Treasurer
Jamey P. Weichert Ph.D. Chief Scientific Officer, Director
Age: 57
Kathryn M. McNeil Vice President - Investor Relations, Public Relations and Corporate Communications
J. Patrick Genn Vice President - Business Development
Age: 56
Kevin Kozak M.D., Ph.D. Chief Medical Officer
Paul L. Berns Independent Director
Age: 47
John P. Neis Independent Director
Age: 57